Across TCGA pan-cancer cohorts, NOTCH2NLA Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NOTCH2NLA data layer compared with 24 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NOTCH2NLA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOTCH2NLA expression acts as an unfavorable survival marker.
BLCA are the cancer types where NOTCH2NLA Mutation most reproducibly stratifies survival.